Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc (NTRB) is a pharmaceutical innovator focused on transdermal drug delivery systems and abuse-deterrent technologies designed to enhance medication safety. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.
Investors and industry stakeholders will find timely updates on AVERSA technology advancements, regulatory milestones, partnership agreements, and product pipeline progress. Our curated news collection ensures access to verified information directly impacting Nutriband’s market position and contributions to opioid safety solutions.
Key content includes earnings reports, intellectual property updates, manufacturing collaborations, and research breakthroughs. Bookmark this page to monitor Nutriband’s progress in developing transdermal therapies that address critical public health challenges while maintaining compliance with global regulatory standards.
Nutriband Inc. (NASDAQ: NTRB) announced its financial results for the fiscal year ending January 31, 2022, reporting record revenue of $1.4 million, up 56% from the previous year. Key achievements include a successful uplisting to Nasdaq in October 2021, raising gross proceeds of approximately $8.7 million, and a partnership with Kindeva Drug Delivery for the AVERSA™ Fentanyl patch. Despite a net loss of $6.4 million, stockholders' equity increased 28% to $11.9 million. The company aims to capitalize on the growing market for abuse deterrent fentanyl patches.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the USPTO published a patent for its AVERSA™ technology aimed at preventing opioid misuse through a transdermal system. The patent, US Patent 11,246,840, was issued on February 15, 2022, and supports the development of the AVERSA Fentanyl patch. Nutriband has entered a feasibility agreement with Kindeva Drug Delivery to incorporate this technology in its lead product candidate.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will participate in Benzinga ALL ACCESS on February 4, 2022, featuring CEO Gareth Sheridan at 10AM ET. The event can be streamed live here. Nutriband specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing their AVERSA™ technology. This technology aims to prevent the misuse and accidental exposure of drugs. For more details, visit www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a notification from the USPTO confirming the issuance of a patent for its AVERSA™ transdermal abuse deterrent technology.
This technology aims to prevent the misuse of drugs by incorporating aversive agents into transdermal patches. The patent secures the company’s lead product, AVERSA™ Fentanyl, which could become the first fentanyl patch with abuse deterrent properties. Nutriband is also expanding its pipeline to include other drugs, enhancing safety against misuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has expanded its product development pipeline for its AVERSA™ abuse deterrent transdermal technology. The lead product, AVERSA Fentanyl, could tap into a market worth $80 - $200 million. Additionally, AVERSA buprenorphine and AVERSA methylphenidate are now part of the pipeline, targeting existing products with abuse potential. The technology aims to deter misuse while ensuring drug availability. A feasibility agreement with Kindeva Drug Delivery has initiated the development of AVERSA Fentanyl, enhancing Nutriband's strategic focus on abuse deterrent formulations.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a feasibility agreement with Kindeva Drug Delivery to develop its lead product, AVERSA™ Fentanyl, utilizing AVERSA™ abuse deterrent technology. This partnership aims to adapt Kindeva's transdermal manufacturing process for AVERSA technology. The technology includes aversive agents to prevent drug abuse and is supported by a robust patent portfolio. CEO Gareth Sheridan expressed optimism about improving safety for fentanyl users while maintaining accessibility for patients in need.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has completed a market assessment for its lead product, Aversa™ Fentanyl, an innovative abuse-deterrent fentanyl transdermal system. Conducted by Health Advances, the analysis suggests that Aversa has the potential for peak annual US sales ranging from $80-200 million within five years post-launch. The company aims to follow a 505(b)(2) NDA regulatory path towards FDA approval, targeting a safer alternative amidst rising concerns over opioid abuse. This product may redefine the transdermal fentanyl market by introducing crucial safety features.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the Korean Intellectual Property Office has issued a full patent for its Abuse and Misuse Deterrent Transdermal System, related to its lead technology AVERSA. This technology aims to prevent opioid abuse through taste aversion methods. A prior notice of allowance was issued in December 2020. Nutriband focuses on developing transdermal pharmaceutical products, with AVERSA designed to mitigate risks associated with abuse, misuse, and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of December 29, 2021, the company had 7,773,962 shares outstanding. This buyback aims to enhance shareholder value and signal confidence in the company's future. Nutriband is focused on developing transdermal pharmaceutical products, particularly an abuse-deterrent fentanyl patch using its AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced plans to offer contract manufacturing services for liquid-based topical products, following its recent cGMP certification. This certification relates to Pharmaceutical OTC GMP, 21 CFR Part 211/210, enhancing the company's manufacturing capabilities. CEO Gareth Sheridan stated that expanding these capabilities aligns with the company's revenue growth strategy for 2022. Nutriband is primarily focused on developing transdermal pharmaceutical products, including its abuse deterrent fentanyl patch utilizing AVERSA technology.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
